Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyun Kuk | - |
dc.contributor.author | Jeong, Myung Ho | - |
dc.contributor.author | Ahn, Young Keun | - |
dc.contributor.author | Kim, Jong Hyun | - |
dc.contributor.author | Chae, Shung Chull | - |
dc.contributor.author | Kim, Young Jo | - |
dc.contributor.author | Hur, Seung Ho | - |
dc.contributor.author | Seong, In Whan | - |
dc.contributor.author | Hong, Taek Jong | - |
dc.contributor.author | Choi, Dong Hoon | - |
dc.contributor.author | Cho, Myeong Chan | - |
dc.contributor.author | Kim, Chong Jin | - |
dc.contributor.author | Seung, Ki Bae | - |
dc.contributor.author | Chung, Wook Sung | - |
dc.contributor.author | Jang, Yang Soo | - |
dc.contributor.author | Rha, Seung Woon | - |
dc.contributor.author | Bae, Jang Ho | - |
dc.contributor.author | Cho, Jeong Gwan | - |
dc.contributor.author | Park, Seung Jung | - |
dc.date.accessioned | 2021-09-08T04:32:48Z | - |
dc.date.available | 2021-09-08T04:32:48Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-03-15 | - |
dc.identifier.issn | 0002-9149 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/116805 | - |
dc.description.abstract | Zotarolimus-eluting stents (ZESs) demonstrated greater in-segment late luminal loss and in-segment binary restenosis rates compared to sirolimus-eluting stents (SESs) in several studies. However, no data are available in direct comparison between the clinical outcomes of the 2 stents in unselected patients with ST-segment elevation acute myocardial infarction (STEMI). The aim of the present study was to compare the clinical outcomes of ZESs and SESs in real-world patients with STEMI. A total of 873 patients with STEMI (306 patients in the ZES group and 567 patients in the SES group) were enrolled in a nationwide prospective Korea Acute Myocardial Infarction Registry (KAMIR) from January 2007 to January 2008. The primary end points were major adverse cardiac events, a composite of all causes of death, myocardial infarction, and target lesion revascularization during a 12-month clinical follow-up. During 1 year of follow-up, the primary end points occurred in 140 patients (16.0%). The use of glycoprotein IIb/IIIa inhibitors and the occurrence of multivessel disease were more common in the SES group. The SES group had a significantly lower incidence of major adverse cardiac events (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.07 to 2.16, p = 0.02), target lesion revascularization (HR 2.16, 95% Cl 1.01 to 4.59, p = 0.046), and target vessel revascularization (HR 2.24, 95% CI 1.18 to 4.24, p = 0.013). However, no significant differences were found in death or myocardial infarction (HR 1.37, 95% CI 0.91 to 2.05, p = 0.129). In conclusion, SESs provided superior angiographic outcomes, translating into better clinical outcomes and negating any change in STEMI patient safety profiles compared to ZESs. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:813-818) | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC | - |
dc.subject | CORONARY-ARTERY-DISEASE | - |
dc.subject | HEART-FAILURE | - |
dc.subject | ENDEAVOR-II | - |
dc.subject | TRIAL | - |
dc.title | Comparison of Outcomes Between Zotarolimus- and Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Acute Myocardial Infarction | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung Woon | - |
dc.identifier.doi | 10.1016/j.amjcard.2009.11.009 | - |
dc.identifier.scopusid | 2-s2.0-77649169152 | - |
dc.identifier.wosid | 000278137300009 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CARDIOLOGY, v.105, no.6, pp.813 - 818 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.citation.title | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 105 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 813 | - |
dc.citation.endPage | 818 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | CORONARY-ARTERY-DISEASE | - |
dc.subject.keywordPlus | HEART-FAILURE | - |
dc.subject.keywordPlus | ENDEAVOR-II | - |
dc.subject.keywordPlus | TRIAL | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.